Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.
about
Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectivesNext generation of weight management medications: implications for diabetes and CVD riskObesity: Current and potential pharmacotherapeutics and targets.2014 EASO Position Statement on the Use of Anti-Obesity Drugs.Review of Pharmacologic Weight Loss Medications in a Patient-Centered Medical Home.
P2860
Management of obesity and cardiometabolic risk - role of phentermine/extended release topiramate.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 February 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Management of obesity and card ...... e/extended release topiramate.
@en
Management of obesity and card ...... e/extended release topiramate.
@nl
type
label
Management of obesity and card ...... e/extended release topiramate.
@en
Management of obesity and card ...... e/extended release topiramate.
@nl
prefLabel
Management of obesity and card ...... e/extended release topiramate.
@en
Management of obesity and card ...... e/extended release topiramate.
@nl
P2093
P2860
P356
P1476
Management of obesity and card ...... ne/extended release topiramate
@en
P2093
Arianne N Sweeting
Eddy Tabet
Ian D Caterson
P2860
P356
10.2147/DMSO.S38979
P50
P577
2014-02-12T00:00:00Z